Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:HSTC OTCMKTS:PPCB OTCMKTS:SKVI OTCMKTS:STLT OTCMKTS:TRGM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSTCHST Global$0.25-9.1%$0.59$0.23▼$1.10$15.89M-1.24213 shs1,973 shsPPCBPropanc Biopharma$4.91-18.2%$4.30$1.25▼$145.46$120K2.522,245 shs3,217 shsSKVISkinvisible$0.20$0.21$0.16▼$0.85$1.08M1.7692 shs3,800 shsSTLTSpotlight Innovation$0.00$0.00▼$0.04N/AN/AN/A100 shsTRGMTargeted Medical Pharma$0.00$0.00▼$0.00N/AN/AN/AN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSTCHST Global-9.09%-16.94%-51.17%-50.98%-76.19%PPCBPropanc Biopharma-18.21%-25.64%-38.66%-55.39%+613,350.00%SKVISkinvisible0.00%-9.09%+13.44%-33.33%-71.01%STLTSpotlight Innovation0.00%0.00%0.00%0.00%0.00%TRGMTargeted Medical Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSTCHST GlobalN/AN/AN/AN/AN/AN/AN/AN/APPCBPropanc BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASKVISkinvisibleN/AN/AN/AN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/AN/AN/AN/ATRGMTargeted Medical PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSTCHST Global 0.00N/AN/AN/APPCBPropanc Biopharma 0.00N/AN/AN/ASKVISkinvisible 0.00N/AN/AN/ASTLTSpotlight Innovation 0.00N/AN/AN/ATRGMTargeted Medical Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSTCHST GlobalN/AN/AN/AN/AN/AN/APPCBPropanc BiopharmaN/AN/AN/AN/A($493.34) per shareN/ASKVISkinvisible$20K54.00N/AN/A($1.86) per share-0.11STLTSpotlight InnovationN/AN/AN/AN/AN/AN/ATRGMTargeted Medical PharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSTCHST Global-$150K-$0.02N/A∞N/AN/AN/AN/AN/APPCBPropanc Biopharma-$1.82MN/A0.00∞N/AN/A-3,652.66%-971.09%N/ASKVISkinvisible-$570K-$0.10N/A∞N/A-2,780.00%N/A-359.02%N/ASTLTSpotlight InnovationN/AN/A0.00N/AN/AN/AN/AN/AN/ATRGMTargeted Medical PharmaN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest STLT, PPCB, TRGM, HSTC, and SKVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q3 2025PPCBPropanc BiopharmaN/A-$12.50N/A-$12.50N/AN/A5/14/2025Q1 2025SKVISkinvisibleN/A-$0.05N/A-$0.05N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSTCHST GlobalN/AN/AN/AN/AN/APPCBPropanc BiopharmaN/AN/AN/AN/AN/ASKVISkinvisibleN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/ATRGMTargeted Medical PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSTCHST GlobalN/AN/AN/APPCBPropanc Biopharma0.012.242.24SKVISkinvisibleN/A0.010.01STLTSpotlight InnovationN/AN/AN/ATRGMTargeted Medical PharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSTCHST GlobalN/APPCBPropanc BiopharmaN/ASKVISkinvisibleN/ASTLTSpotlight InnovationN/ATRGMTargeted Medical PharmaN/AInsider OwnershipCompanyInsider OwnershipHSTCHST Global65.82%PPCBPropanc Biopharma0.10%SKVISkinvisible53.00%STLTSpotlight InnovationN/ATRGMTargeted Medical Pharma69.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSTCHST Global157.77 million19.75 millionNot OptionablePPCBPropanc Biopharma120,00019,000Not OptionableSKVISkinvisible25.40 million2.54 millionNot OptionableSTLTSpotlight Innovation4N/AN/ANot OptionableTRGMTargeted Medical Pharma30N/AN/ANot OptionableSTLT, PPCB, TRGM, HSTC, and SKVI HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comMedia Sentiment Over TimeSTLT, PPCB, TRGM, HSTC, and SKVI Company DescriptionsHST Global OTCMKTS:HSTC$0.25 -0.03 (-9.09%) As of 07/15/2025 02:23 PM EasternHST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.Propanc Biopharma OTCMKTS:PPCB$4.91 -1.09 (-18.21%) As of 07/15/2025 03:50 PM EasternPropanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.Skinvisible OTCMKTS:SKVI$0.20 0.00 (0.00%) As of 07/15/2025 03:37 PM EasternSkinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.Spotlight Innovation OTCMKTS:STLTSpotlight Innovation Inc., a pharmaceutical company, acquires and develops proprietary therapies to address unmet medical needs with an emphasis on rare, emerging, and neglected diseases. It identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations, and contract manufacturing organizations, as well as pursues product commercialization opportunities, including out-licensing and strategic partnerships. The company is developing Crotoxin, which is in Phase I clinical study for the treatment of cancer. It also develops various compounds for the treatment of viral infections, including Zika virus infection; and products derived from cobra venom to treat chronic pain. Spotlight Innovation Inc. has a license agreement with Indiana University Research and Technology Corporation to commercialize STL-182, an orally-available small molecule that might have therapeutic potential for treating spinal muscular atrophy. The company is based in Urbandale, Iowa.Targeted Medical Pharma OTCMKTS:TRGMTargeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers' compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
